Gerresheimer AG GXI.DE
Composite 29/100; the shares have moved about 67% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 12/100 — a strong mark against it.
Valuation ranks 52/100 — a slight point in its favour.
Quality ranks 12/100 — a strong mark against it. Balance-sheet strength ranks 15/100 — a strong mark against it. Growth ranks 27/100 — a moderate mark against it.
What the company does Gerresheimer AG designs and manufactures drug containment and delivery systems, including plastic and glass packaging, prefillable syringes, auto-injectors, and diagnostic devices. Its three divisions—Plastics & Devices, Primary Packaging Glass, and Advanced Technologies—serve pharmaceutical, diagnostic, and cosmetic markets globally.
Key financials Gross margin is 23.6% but net margin is negative 13.8% on revenue growth of 22.0%. ROE is negative 24.4%, ROA is 1.6%, and ROCE is negative 6.7%. Debt/Equity is 2.08x with net debt/EBITDA at 5.94x and interest coverage of negative 2.14x.
Stock health The stock shows mixed momentum: +14.83% over 3 months, +9.91% over 6 months, but -37.15% over 12 months and -39.71% below its 52-week high. RSI(14) is 53.70, indicating neutral momentum.
Price vs fair value The stock trades at a discount of 49.10% to our fair-value estimate of 42.02 and at a PREMIUM of 10.35% versus the analyst 12-month target of 25.26. - Sale of two packaging businesses for $1.7bn to Apax (Packaging Gateway, Packaging Dive) - Valuation percentile of 65.9/100 signals attractive pricing vs the screened universe - Overall Sidereavia score of 31.5 reflects poor quality but attractive valuation
Looking forward Forward P/E is 10.06x and EV/EBITDA is 10.17x, below sector medians, but negative margins and high leverage remain headwinds. Analysts expect a rebound tied to asset monetization and restructuring benefits.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.